REGENXBIO (NASDAQ:RGNX - Get Free Report)'s stock had its "overweight" rating reissued by stock analysts at Morgan Stanley in a report issued on Friday, Marketbeat reports. They currently have a $22.00 price objective on the biotechnology company's stock. Morgan Stanley's target price points to a potential upside of 128.45% from the company's previous close.
A number of other equities analysts also recently commented on RGNX. HC Wainwright lifted their price target on REGENXBIO from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Raymond James restated an "outperform" rating and issued a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. StockNews.com upgraded REGENXBIO from a "sell" rating to a "hold" rating in a research note on Friday, September 20th. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Tuesday, October 22nd. Finally, Barclays decreased their target price on REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, August 5th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $35.64.
View Our Latest Research Report on REGENXBIO
REGENXBIO Price Performance
NASDAQ:RGNX traded down $1.51 during mid-day trading on Friday, reaching $9.63. The stock had a trading volume of 1,277,367 shares, compared to its average volume of 605,350. The company has a market capitalization of $477.07 million, a price-to-earnings ratio of -2.04 and a beta of 1.23. REGENXBIO has a 1-year low of $8.53 and a 1-year high of $28.80. The stock's 50 day simple moving average is $10.54 and its two-hundred day simple moving average is $12.35.
Insider Buying and Selling
In related news, Director Argeris N. Karabelas sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the sale, the director now owns 11,286 shares of the company's stock, valued at $130,466.16. The trade was a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 13.13% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On REGENXBIO
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock valued at $28,000 after buying an additional 1,656 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of REGENXBIO in the first quarter valued at $56,000. nVerses Capital LLC increased its holdings in shares of REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company's stock valued at $36,000 after buying an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of REGENXBIO by 64.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company's stock valued at $100,000 after buying an additional 3,720 shares in the last quarter. Finally, Diversified Trust Co bought a new position in shares of REGENXBIO in the second quarter valued at $121,000. Institutional investors own 88.08% of the company's stock.
About REGENXBIO
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Read More
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
